Delphinidin, One of the Major Anthocyanidins, Prevents Bone Loss through the Inhibition of Excessive Osteoclastogenesis in Osteoporosis Model Mice

Anthocyanins, one of the flavonoid subtypes, are a large family of water-soluble phytopigments and have a wide range of health-promoting benefits. Recently, an anthocyanin-rich compound from blueberries was reported to possess protective property against bone loss in ovariectomized (OVX) animal mode...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 9; no. 5; p. e97177
Main Authors Moriwaki, Sawako, Suzuki, Keiko, Muramatsu, Masashi, Nomura, Atsushi, Inoue, Fumihide, Into, Takeshi, Yoshiko, Yuji, Niida, Shumpei
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 13.05.2014
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Anthocyanins, one of the flavonoid subtypes, are a large family of water-soluble phytopigments and have a wide range of health-promoting benefits. Recently, an anthocyanin-rich compound from blueberries was reported to possess protective property against bone loss in ovariectomized (OVX) animal models. However, the active ingredients in the anthocyanin compound have not been identified. Here we show that delphinidin, one of the major anthocyanidins in berries, is a potent active ingredient in anti-osteoporotic bone resorption through the suppression of osteoclast formation. In vitro examinations revealed that delphinidin treatment markedly inhibited the differentiation of RAW264.7 cells into osteoclasts compared with other anthocyanidins, cyanidin and peonidin. Oral administration of delphinidin significantly prevented bone loss in both RANKL-induced osteoporosis model mice and OVX model mice. We further provide evidence that delphinidin suppressed the activity of NF-κB, c-fos, and Nfatc1, master transcriptional factors for osteoclastogenesis. These results strongly suggest that delphinidin is the most potent inhibitor of osteoclast differentiation and will be an effective agent for preventing bone loss in postmenopausal osteoporosis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: AN and FI are employees of Nihon Seiyaku Kogyo Co., Ltd. Tama Biochemical Co. Ltd., who donated experimental material Cassis-extract-35, also declared that no competing interests exist. This does not alter adherence to all PLOS ONE policies on sharing data and materials.
Current address: Department of Cancer Genetics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York, United States of America
Conceived and designed the experiments: SN. Performed the experiments: SM KS MM YY. Analyzed the data: KS TI YY. Contributed reagents/materials/analysis tools: AN FI. Wrote the paper: SN.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0097177